Vorasidenib treatment shows 96% disease control in grade 2 glioma study

A clinical study presented at the European Association of Neuro-Oncology (EANO) congress in Rome has shown that a new treatment can control disease in 96% of patients with grade 2 gliomas.

The research, conducted across seven hospitals in Andalusia and reported by the Sociedad Andaluza de Oncología Médica (SAOM), analyzed 58 patients treated between 2024 and 2025. The drug used, vorasidenib, targets mutated forms of the IDH1 and IDH2 enzymes.

While the results demonstrate significant tumor stabilization, experts note that the study was conducted in real-world clinical practice with a small patient group; therefore, it should not be interpreted as a 96% cure rate. Grade 2 gliomas are common malignant brain tumors in adults under 50, and the median overall survival for the studied group was approximately 13 years.